Please enable JavaScript to continue using this application.

Compare $RARE vs $STOK | Chartloom

Compare

$RARE vs $STOK

Ultragenyx Pharmaceutical Inc · Stoke Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

STOK

Stoke Therapeutics Inc

Compare $RARE vs $STOK

Comparing Ultragenyx Pharmaceutical Inc and Stoke Therapeutics Inc

RAREUltragenyx Pharmaceutical Inc

STOKStoke Therapeutics Inc

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

STOKStoke Therapeutics Inc

Market cap

$1.54B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

47.27x

Rev growth (TTM)

-86.2%

YTD performance

-19.9%

52W performance

-18.9%

FCF yield

-11.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RARE

STOK

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

STOK

Stoke Therapeutics Inc

Market Cap

RARE$1.52B

STOK$1.54B

Enterprise Value

RARE$2.54B

STOK$1.43B

Price

RARE$15.48

STOK$24.74

P/E Ratio

RAREN/A

STOKN/A

P/S Ratio

RARE2.13x

STOK55.85x

EV/Sales

RARE3.54x

STOK51.86x

EV/EBITDA

RARE0.00x

STOK53.69x

P/B Ratio

RARE163.83x

STOK4.78x

P/FCF Ratio

RAREN/A

STOKN/A

EV/FCF

RARE-5.14x

STOK-7.92x

PEG Ratio

RAREN/A

STOKN/A

Forward P/E (NTM)

RAREN/A

STOKN/A

Forward P/S (NTM)

RARE1.74x

STOK47.27x

Revenue (TTM)

RARE$717M

STOK$28M

Revenue Growth (YoY)

RARE17.5%

STOK-86.2%

Forward Rev Growth

RARE27.7%

STOK62.9%

Gross Margin (TTM)

RARE83.1%

STOK0.0%

Operating Margin (TTM)

RARE0.0%

STOK0.0%

EBITDA Margin (TTM)

RARE-69.0%

STOK-803.4%

Net Margin (TTM)

RARE-81.7%

STOK-753.6%

FCF Margin (TTM)

RARE-68.9%

STOK-654.9%

Net Income (TTM)

RARE$-586M

STOK$-208M

FCF (TTM)

RARE$-494M

STOK$-181M

EPS (TTM)

RARE-$5.75

STOK-$3.15

ROE (TTM)

RARE-41417.0%

STOK-5936.0%

ROA (TTM)

RARE-4437.0%

STOK-5146.0%

ROIC (TTM)

RARE-5861.0%

STOK-5936.0%

Cash

RARE$125M

STOK$110M

Debt

RARE$1.14B

STOK$0

Net Cash/Debt

RARE$-1.02B

STOK$110M

Current Ratio (TTM)

RARE1.73x

STOK7.69x

Quick Ratio (TTM)

RARE1.43x

STOK7.34x

Debt/Equity (TTM)

RARE90.54x

STOK0.00x

Debt/Assets (TTM)

RARE0.0%

STOK0.0%

Interest Coverage (TTM)

RAREN/A

STOKN/A

Net Debt/EBITDA (TTM)

RARE0.00x

STOK0.00x

Beta

RARE0.35

STOK1.36

52W Performance

RARE-49.8%

STOK-18.9%

YTD Performance

RARE-34.4%

STOK-19.9%

% from 52W High

RARE-61.2%

STOK-38.5%

% from 52W Low

RARE21.6%

STOK21.8%

Asset Turnover (TTM)

RARE0.54x

STOK0.07x

FCF Yield (TTM)

RARE-32.4%

STOK-11.7%

Earnings Yield (TTM)

RARE-38.4%

STOK-13.5%

Dividend Yield (TTM)

RAREN/A

STOKN/A

Rule of 40

RARE-51.4

STOK-741.1

EV/GP/RG

RARE0.17

STOKN/A

Ticker research

View RARE research View STOK research

Metric	RARE Ultragenyx Pharmaceutical Inc	STOK Stoke Therapeutics Inc
Market & Valuation
Market Cap	$1.52B	$1.54B
Enterprise Value	$2.54B	$1.43B
Price	$15.48	$24.74
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	55.85x
EV/Sales	3.54x	51.86x
EV/EBITDA	0.00x	53.69x
P/B Ratio	163.83x	4.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	47.27x
Revenue & Growth
Revenue (TTM)	$717M	$28M
Revenue Growth (YoY)	17.5%	-86.2%
Forward Rev Growth	27.7%	62.9%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-803.4%
Net Margin (TTM)	-81.7%	-753.6%
FCF Margin (TTM)	-68.9%	-654.9%
Net Income (TTM)	$-586M	$-208M
FCF (TTM)	$-494M	$-181M
EPS (TTM)	-$5.75	-$3.15
ROE (TTM)	-41417.0%	-5936.0%
ROA (TTM)	-4437.0%	-5146.0%
ROIC (TTM)	-5861.0%	-5936.0%
Financial Health
Cash	$125M	$110M
Debt	$1.14B	$0
Net Cash/Debt	$-1.02B	$110M
Current Ratio (TTM)	1.73x	7.69x
Quick Ratio (TTM)	1.43x	7.34x
Debt/Equity (TTM)	90.54x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	1.36
52W Performance	-49.8%	-18.9%
YTD Performance	-34.4%	-19.9%
% from 52W High	-61.2%	-38.5%
% from 52W Low	21.6%	21.8%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.07x
FCF Yield (TTM)	-32.4%	-11.7%
Earnings Yield (TTM)	-38.4%	-13.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-741.1
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View STOK research

Valuation

P/S Ratio

RARE

2.13x

STOK

55.85x

EV/FCF

STOK

-7.92x

RARE

-5.14x

Growth & revenue

Revenue Growth TTM

RARE

17.5%

STOK

-86.2%

Forward Revenue Growth

STOK

62.9%

RARE

27.7%

Profitability & performance

Gross Margin

RARE

83.1%

STOK

0.0%

ROE

STOK

-5936.0%

RARE

-41417.0%

FCF Yield %

STOK

-11.7%

RARE

-32.4%

52-Week Performance

STOK

-18.9%

RARE

-49.8%

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

STOK

Stoke Therapeutics Inc

Market Cap

RARE$1.52B

STOK$1.54B

Enterprise Value

RARE$2.54B

STOK$1.43B

Price

RARE$15.48

STOK$24.74

P/E Ratio

RAREN/A

STOKN/A

P/S Ratio

RARE2.13x

STOK55.85x

EV/Sales

RARE3.54x

STOK51.86x

EV/EBITDA

RARE0.00x

STOK53.69x

P/B Ratio

RARE163.83x

STOK4.78x

P/FCF Ratio

RAREN/A

STOKN/A

EV/FCF

RARE-5.14x

STOK-7.92x

PEG Ratio

RAREN/A

STOKN/A

Forward P/E (NTM)

RAREN/A

STOKN/A

Forward P/S (NTM)

RARE1.74x

STOK47.27x

Revenue (TTM)

RARE$717M

STOK$28M

Revenue Growth (YoY)

RARE17.5%

STOK-86.2%

Forward Rev Growth

RARE27.7%

STOK62.9%

Gross Margin (TTM)

RARE83.1%

STOK0.0%

Operating Margin (TTM)

RARE0.0%

STOK0.0%

EBITDA Margin (TTM)

RARE-69.0%

STOK-803.4%

Net Margin (TTM)

RARE-81.7%

STOK-753.6%

FCF Margin (TTM)

RARE-68.9%

STOK-654.9%

Net Income (TTM)

RARE$-586M

STOK$-208M

FCF (TTM)

RARE$-494M

STOK$-181M

EPS (TTM)

RARE-$5.75

STOK-$3.15

ROE (TTM)

RARE-41417.0%

STOK-5936.0%

ROA (TTM)

RARE-4437.0%

STOK-5146.0%

ROIC (TTM)

RARE-5861.0%

STOK-5936.0%

Cash

RARE$125M

STOK$110M

Debt

RARE$1.14B

STOK$0

Net Cash/Debt

RARE$-1.02B

STOK$110M

Current Ratio (TTM)

RARE1.73x

STOK7.69x

Quick Ratio (TTM)

RARE1.43x

STOK7.34x

Debt/Equity (TTM)

RARE90.54x

STOK0.00x

Debt/Assets (TTM)

RARE0.0%

STOK0.0%

Interest Coverage (TTM)

RAREN/A

STOKN/A

Net Debt/EBITDA (TTM)

RARE0.00x

STOK0.00x

Beta

RARE0.35

STOK1.36

52W Performance

RARE-49.8%

STOK-18.9%

YTD Performance

RARE-34.4%

STOK-19.9%

% from 52W High

RARE-61.2%

STOK-38.5%

% from 52W Low

RARE21.6%

STOK21.8%

Asset Turnover (TTM)

RARE0.54x

STOK0.07x

FCF Yield (TTM)

RARE-32.4%

STOK-11.7%

Earnings Yield (TTM)

RARE-38.4%

STOK-13.5%

Dividend Yield (TTM)

RAREN/A

STOKN/A

Rule of 40

RARE-51.4

STOK-741.1

EV/GP/RG

RARE0.17

STOKN/A

Ticker research

View RARE research View STOK research

Metric	RARE Ultragenyx Pharmaceutical Inc	STOK Stoke Therapeutics Inc
Market & Valuation
Market Cap	$1.52B	$1.54B
Enterprise Value	$2.54B	$1.43B
Price	$15.48	$24.74
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	55.85x
EV/Sales	3.54x	51.86x
EV/EBITDA	0.00x	53.69x
P/B Ratio	163.83x	4.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	47.27x
Revenue & Growth
Revenue (TTM)	$717M	$28M
Revenue Growth (YoY)	17.5%	-86.2%
Forward Rev Growth	27.7%	62.9%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-803.4%
Net Margin (TTM)	-81.7%	-753.6%
FCF Margin (TTM)	-68.9%	-654.9%
Net Income (TTM)	$-586M	$-208M
FCF (TTM)	$-494M	$-181M
EPS (TTM)	-$5.75	-$3.15
ROE (TTM)	-41417.0%	-5936.0%
ROA (TTM)	-4437.0%	-5146.0%
ROIC (TTM)	-5861.0%	-5936.0%
Financial Health
Cash	$125M	$110M
Debt	$1.14B	$0
Net Cash/Debt	$-1.02B	$110M
Current Ratio (TTM)	1.73x	7.69x
Quick Ratio (TTM)	1.43x	7.34x
Debt/Equity (TTM)	90.54x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	1.36
52W Performance	-49.8%	-18.9%
YTD Performance	-34.4%	-19.9%
% from 52W High	-61.2%	-38.5%
% from 52W Low	21.6%	21.8%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.07x
FCF Yield (TTM)	-32.4%	-11.7%
Earnings Yield (TTM)	-38.4%	-13.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-741.1
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View STOK research